An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment.

Trial Profile

An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Octreotide (Primary)
  • Indications Endocrine gland neoplasms; Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Status changed from recruiting to active, no longer recruiting as per results presented at the 51st Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2015 Results (4-year update) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top